Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 181, Issue 2, Pages 391-401
Publisher
Springer Science and Business Media LLC
Online
2020-04-22
DOI
10.1007/s10549-020-05638-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response
- (2019) Krithika N. Kodumudi et al. Frontiers in Immunology
- Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence – Implications for vaccine trial design
- (2018) O. Jackson Doreen et al. CLINICAL IMMUNOLOGY
- Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
- (2017) Sotirios P. Fortis et al. Journal for ImmunoTherapy of Cancer
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence
- (2016) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- New Strategies in Breast Cancer: Immunotherapy
- (2016) L. Pusztai et al. CLINICAL CANCER RESEARCH
- Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence
- (2016) Elizabeth A. Mittendorf et al. Oncotarget
- Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics
- (2015) Maurizio Zanetti JOURNAL OF IMMUNOLOGY
- Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
- (2014) E. A. Mittendorf et al. ANNALS OF ONCOLOGY
- Immunological subtypes in breast cancer are prognostic for invasive ductal but not for invasive lobular breast carcinoma
- (2014) C C Engels et al. BRITISH JOURNAL OF CANCER
- Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer
- (2010) S. A. Perez et al. CLINICAL CANCER RESEARCH
- Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide
- (2010) Jeremy D. Gates et al. VACCINE
- Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
- (2008) G. E. Peoples et al. CLINICAL CANCER RESEARCH
- Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine
- (2008) Jarrod P. Holmes et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started